# Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

> **NCT00771810** · PHASE2 · COMPLETED · sponsor: **Tarix Pharmaceuticals** · enrollment: 34 (actual)

## Conditions studied

- Thrombocytopenia
- Neutropenia
- Lymphopenia
- Anemia

## Interventions

- **DRUG:** TXA127
- **DRUG:** TXA127
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00771810
- **Lead sponsor:** Tarix Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00771810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00771810, "Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00771810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*